For ads-free news, click here.
From Breitbart: An Israeli biotech firm says it is nearing human trials for a breakthrough drug that could extend human lifespan by up to 30 percent by targeting the age-regulating protein SIRT-6, which the company says would also improve brain function, organ health, and overall vitality.
On Friday, Israeli news site N12 reported that Tel Aviv-based Sirtlab is preparing to launch clinical trials on a drug designed to stimulate SIRT-6, a protein associated with youth, vitality, and disease resistance. The treatment could be available within three years, pending successful trials and regulatory approval.
Professor Haim Cohen, the company’s chief scientist and head of the Sagol Institute for Longevity Research, said the compound has already restored SIRT-6 levels in test animals to those seen in young specimens — dramatically extending both lifespan and quality of life.
“When this protein is more active in old age, not only do you live longer — you live healthier,” Cohen explained. Benefits observed included sharper memory, improved liver function, and even renewed hair growth.
While some experts remain cautiously optimistic, Sirtlab has raised millions in funding and is now accelerating its timeline using the Israeli investment platform PipelBiz.
READ MORE from Breitbart.
Israel’s Health Tech is Reshaping the Future – Are You Paying Attention? 🏥💡
At MIXiii 2024, Stephanie Hallett from the @usembassyjlm made it clear: the world is looking to Israel for the next big breakthroughs in health tech. From AI-powered diagnostics to biotech innovations,… pic.twitter.com/GF1fuznLDy
— IsraelTech (@IsraelTech) March 27, 2025
This week, multiple tech conferences are taking place in Israel, bringing together many of the most innovative and disruptive global leaders in tech.
This should not be surprising. Even after 537 days of war, Israel remains number 1 in start-ups per capita, and home to over 500… pic.twitter.com/ekyZYxDmjO
— Asher Fredman אשר פרדמן (@fredman_a) March 27, 2025
There are multiple reports posted on social media about the SIRT-6 gene therapy.
Genflow begins SIRT6 gene therapy trial in dogs
Trial aims to demonstrate capacity to extend healthspan in older animals as company continues to progress towards human trials.#longevity #healthspan #SIRT6 #dogshttps://t.co/8Dvkjgqiej pic.twitter.com/OUfXIpALeW— Longevity Technology (@LongevityTech) March 27, 2025
🚨New paper🚨Our new study with @Phil_Cole_Lab uncovers how SIRT6 dynamically adapts structurally and enzymatically to target diverse histone acylations (e.g., H3K27ac) within nucleosomes.@ZhipengA @MarkertJon https://t.co/uSejRU9n7x #Chromatin #SIRT6 #CryoEM pic.twitter.com/e73B4fIHfs
— Lucas Farnung (@LucasFarnung) March 28, 2025
SIRT6 – if you dont read about it now, you will only find out when CNN covers it in 2035 pic.twitter.com/fD9KHPcn84
— DoNotAge.org (@Do_Not_Age) February 2, 2025
A team has discovered how the enzyme #SIRT6 in #macrophages supports brown fat function in mice, showing that the enzyme is essential to maintain concentrations of the hormone #norepinephrine in brown fat tissue. #HubeiUniversity https://t.co/BpScqogqRq pic.twitter.com/zBBVYT1sUK
— Science Signaling (@scisignal) March 23, 2025
even more news coming in february RE sirt 6 trials
there’s a reason this is the hottest ingredient in longevity 🔥 pic.twitter.com/51FI8cpSxj
— DoNotAge.org (@Do_Not_Age) January 28, 2025
🌍 𝗧𝗵𝗲 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗚𝗟𝗣-𝟭-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀
🔬 At #Immunic, we are exploring how #SIRT6 modulation could impact #GLP1 levels, with our drug candidate #IMU856 offering potential benefits for #WeightManagement.
💊 As #obesity and… pic.twitter.com/vykL072H9i
— Immunic Therapeutics (@ImmunicInc) March 26, 2025
The Role and Molecular Pathways of SIRT6 in Senescence and Age-related Diseaseshttps://t.co/GnyJbN4XGa
— Agingdoc⭐David Barzilai🔔MD PhD MS MBA DipABLM🩺 (@agingdoc1) February 25, 2025
Follow us on X (Formerly Twitter.)
The DML News App: www.X.com/DMLNewsApp
The Dennis Michael Lynch Podcast archive is available below, with the most recent on top. Never miss an episode. Subscribe to the show by downloading The DML News App or go to Apple Podcasts.
